<- Go Home
Imarx Therapeutics, Inc.
As of May 14, 2010, Imarx Therapeutics, Inc. was acquired by Sycamore Films, Inc., in a reverse merger transaction. Previously, the company focused on the research, development, and commercialization of therapies for stroke and other vascular disorders using its microbubble technology. Its lead program, SonoLysis, involves the administration of its MRX-801 microspheres and ultrasound to break up blood clots and restore blood flow to oxygen deprived tissues. The company was founded in 1999 and is based in Redmond, Washington.
Market Cap
$175.0K
Volume
31.1K
Cash and Equivalents
$184.0K
EBITDA
-$689.0K
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$0.04
52 Week Low
$0.01
Dividend
N/A
Price / Book Value
3.50
Price / Earnings
-0.39
Price / Tangible Book Value
3.50
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
-$694.0K
Return on Equity
264.78%
Return on Assets
-102.66
Cash and Short Term Investments
$184.0K
Debt
N/A
Equity
$50.0K
Revenue
N/A
Unlevered FCF
-$368.8K
Sector
Pharmaceuticals
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium